NHS Digital reports latest data for the NHS Innovation Scorecard

NHS Digital has released the latest tranche of data for its Innovation Scorecard.

The Scorecard tracks and maps uptake and usage of medicines and medical devices which have been recommended by the National Institute for Health and Care Excellence (NICE) through Technology Appraisals (TAs), helping to identify any variations down to the level of Sustainability and Transformation Partnerships (STPs) and Clinical Commissioning Groups (CCGs). Once variations are identified they can be either justified, challenged or acted on accordingly.

Over the 12 months between October 2017 to September 2018 when compared to the previous 12 months, the Innovation Scorecard findings were:
Thanks to data from the the scorecard, NHS Digital have identified a number of trends in the October 2017 to September 2018 data, compared with the preceding year:

  • 74% of medicines were prescribed more (84 individual medicines prescribed from the 114)
  • All medicine groupings were used more, including a 38% increase in the use of novel anticoagulation (NOAC) drugs in Primary Care, and a 34% increase in the use of diabetes medicines
  • All but one one medical technologies were used more
  • The Innovation scorecard release also included seven new medicines (five drugs for cancer, one for multiple sclerosis, and one in dermatology), however no new medical technologies were released on the Innovation Scorecard

The estimates report compares the expected usage of NICE recommended medicines to the actual volume of medicines used in the NHS in England. The release includes five single medicine estimates and four estimates for combination therapies.

For the 12 month period from October 2017 to September 2018:

  • Medicine use for four of the nine estimates is lower than expected
    • sacubitril
    • triflurinide-tipiracil
    • alirocumab + evolocumab
    • etelcalcetide
  • Medicine use for four estimates is within the expected range
    • vedolizumab
    • afatanib + erlotinib + gefitinib + osimertinib
    • rifaximin
    • dimethyl fumarate + teriflunomide
  • Medicine use for one estimate is higher than expected
    • abiraterone + cabazitaxe + enzalutamide

The full report can be accessed here

Tagged with

Published on 12. April 2019 in News, News UK